Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):344–350. doi: 10.1158/1055-9965.EPI-15-0470

Table 1.

Characteristics of PROSPR participants with a positive fecal occult blood test, 2011–2012 (N=62,384)

Characteristic Overall N=62,384 GH N=2,707 (4.34%) KPNC N=32,263 (51.72%) KPSC N=27,013 (43.30%) PHHS-UTSW N=401 (0.64%)

Col. % Col. % Col. % Col. % Col. %
Age (years) at positive test
 50–54 20.39 14.85 20.03 21.19 33.17
 55–59 20.21 17.33 20.11 20.40 34.41
 60–64 20.51 20.58 21.16 19.54 32.42
 65–69 17.35 17.55 17.89 16.94 0
 70–75 16.29 16.11 16.46 16.36 0
 76–84 4.22 10.53 3.52 4.49 0
 85–89 1.03 3.07 0.83 1.07 0
Gender
 Female 47.76 48.69 47.20 48.12 62.84
 Male 52.24 51.31 52.80 51.88 37.16
 Unknown 0 0 0.01 0 0
Charlson comorbidity score in calendar year before positive test
 Unknown 10.21 6.91 9.03 11.26 56.36
 0 51.78 48.13 55.90 47.71 19.20
 1 17.32 16.00 17.77 16.95 14.96
 2 9.53 11.34 9.22 9.81 3.99
 3+ 11.16 17.62 8.09 14.26 5.49
Race/ethnicity
 NH White 54.29 76.41 57.75 48.56 14.46
 Hispanic 18.50 4.21 12.49 26.95 29.43
 NH Asian/Pacific Islander 13.11 8.64 15.71 10.58 4.24
 NH Black 8.14 4.25 6.91 9.36 51.12
 NH Other 0.63 3.92 0.66 0.28 0.25
 Unknown/Missing 5.33 2.84 6.48 4.26 0.50
Body mass index (kg/m2) in calendar year before positive test
 <25 19.42 19.87 20.40 18.28 14.46
 25 to <30 30.20 32.03 29.97 30.27 31.17
 30 to <35 20.86 23.01 20.32 21.21 26.18
 35+ 16.43 21.98 15.77 16.49 27.43
 Missing 13.09 3.10 13.53 13.75 0.75
Type of fecal blood test
 FIT 98.05 68.86 98.84 100.00 99.75
 Guaiac 1.95 31.14 1.16 0.00 0.25
Prior colorectal cancer screening
 No 22.36 37.46 20.83 22.37 43.14
 Yes 77.64 62.54 79.17 77.63 56.86

FIT: fecal immunohistochemical test; GH: Group Health; KPNC: Kaiser Permanente Northern California; KPSC: Kaiser Permanente Southern California; NH: non-Hispanic; PHHS-UTWS: Parkland Health and Hospital System – University of Texas Southwestern Medical Center; PROSPR: Population-Based Research Optimizing Screening through Personalized Regimens